NCT07220278 Ongoing Dynamic Choice to Address HIV Treatment Interruption in Malawi
| NCT ID | NCT07220278 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Los Angeles |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2028-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2025-11-17 with a primary completion date of 2028-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Repeat and prolonged treatment interruption (TI) is common and the major threat to HIV epidemic control in eastern and southern Africa. The proposed project will test an innovative long-term dynamic choice intervention for ART clients experiencing TI in Malawi. Findings will provide essential information on how to improve sustained retention among TI client, a critical step to curbing the HIV epidemic. TI clients need long-term, responsive interventions. There are no one-size fits all intervention to support long-term care for TI clients because clients experience vastly different and changing barriers to care. While health facilities do have limited capacity for adding new services, existing services can be packaged differently to meet clients' needs. Long-term, dynamic choice of services is one way to provide responsive services and promotes client ownership over care. The investigators propose to give TI clients long-term, dynamic choice of what services they receive and how they receive it (drawing from key building blocks of DSD). Long-term, dynamic choice puts clients in the driver's seat and may be the best practical strategy to provide long-term and responsive TI interventions that are tailored to clients' evolving life circumstances. Dynamic choice is frequently used for HIV prevention and family planning products, whereby clients select the type of health product that works best for them (i.e., condoms, injectables, etc.). Choice of these services is strongly associated with improved outcomes. The goal of this clinical trial is to determine if CHOICE can improve outcomes in TI clients, compared to standard of care (SOC). Participants will be randomly assigned to either the CHOICE or SOC group, and follow them for 12 months. The primary outcome will be viral suppression at 12 months.
Eligibility Criteria
Inclusion Criteria: * 15 years of age or older * living with HIV; * initiated ART for the first time\>3-months ago (i.e., not a new initiate); * non-pregnant; * experienced Treatment Interuptions during their most recent ARTappointment (\>28 days late). Exclusion Criteria: * pregnant women because the ART/antenatal care (ANC) programs are integrated and require additional considerations and linkages with antenatal services.
Contact & Investigator
Kathryn L Dovel, PhD
PRINCIPAL INVESTIGATOR
University of California, Los Angeles
Frequently Asked Questions
Who can join the NCT07220278 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07220278 currently recruiting?
Yes, NCT07220278 is actively recruiting participants. Contact the research team at kdovel@mednet.ucla.edu for enrollment information.
Where is the NCT07220278 trial being conducted?
This trial is being conducted at Lilongwe, Malawi.
Who is sponsoring the NCT07220278 clinical trial?
NCT07220278 is sponsored by University of California, Los Angeles. The principal investigator is Kathryn L Dovel, PhD at University of California, Los Angeles. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.